Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies.
Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies.
复制标题
DOI：
10.1371/journal.pone.0201425
复制
发表时间：
2018
期刊：
影响因子：
3.7
通讯作者：
Gregorc V
中科院分区：
文献类型：
--
作者：
Petrelli F;Lazzari C;Ardito R;Borgonovo K;Bulotta A;Conti B;Cabiddu M;Capitanio JF;Brighenti M;Ghilardi M;Gianni L;Barni S;Gregorc V
与其他 NSCLC 亚型患者相比，间变性淋巴瘤激酶重排 (ALK+) 非小细胞肺癌 (NSCLC) 患者发生脑转移 (BM) 的风险更高。 ALK 抑制剂对 ALK+ NSCLC 引起的 BM 具有活性。我们对文献进行了系统回顾，旨在评估 ALK 抑制剂对 BM 的功效。使用数据库 Pubmed、EMBASE、Web of Science、Cochrane Library 和 SCOPUS 对文献进行系统检索。检索了报告 ALK 抑制剂在 NSCLC BM 中的活性的相关出版物。根据固定或随机效应模型，使用事件数/可评估患者数来汇总数据。通过总有效率（ORR）、疾病控制率（DCR：ORR+疾病稳定率）、中位无进展生存期（PFS）和总生存期（OS）来评估颅内肿瘤反应。主要终点是颅内总体缓解率（IC ORR）。总共分析了 21 项研究中的 1,016 名 BM 患者。在一线治疗中接受 ALK 抑制剂的患者中，汇总 IC ORR 为 39.17% (95%CI 13.1–65.2%)，而在其他线中观察到的汇总 IC ORR 为 44.2% (95%CI 33.3–55.1%)。未接受治疗和接受过治疗的患者的颅内疾病控制率 (IC DCR) 分别为 70.3% 和 78.2%。未接受脑部放疗的患者的 IC ORR 为 49.0%。基于这些数据，无论采用哪种治疗方案，ALK 抑制剂对于具有相似 IC ORR 和 IC DCR 的初治患者和接受过治疗的患者均有效。
Patients with anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) have a higher risk of developing brain metastases (BMs) than patients with other NSCLC sub-types. ALK inhibitors have activity in BMs due to ALK+ NSCLC. We performed a systematic review of the literature with the aim of assessing the efficacy of ALK inhibitors on BMs. A systematic search of the literature was performed using the databases Pubmed, EMBASE, Web of Science, The Cochrane Library, and SCOPUS. Relevant publications reporting activity of ALK inhibitors in NSCLC BMs were retrieved. Data were pooled using the number of events/number of evaluable patients according to fixed or random effect models. Intracranial tumour response was assessed through overall response rate (ORR), disease control rate (DCR: ORR + stable disease rate), median progression-free survival (PFS), and overall survival (OS). The primary endpoint was intracranial overall response rate (IC ORR). A total of 1,016 patients with BMs from 21 studies were analysed. In patients receiving ALK inhibitors in the first line setting, the pooled IC ORR was 39.17% (95%CI 13.1–65.2%), while the pooled IC ORR observed in further lines was 44.2% (95%CI 33.3–55.1%). Intracranial disease control rate (IC DCR) was 70.3% and 78.2% in naïve and pre-treated patients, respectively. Patients who had not received brain radiation attained an IC ORR of 49.0%. Based on these data, ALK inhibitors are effective in both naive and pre-treated patients with similar IC ORR and IC DCR, irrespective of the line of therapy.
登录
查看更多内容
EGFR突变或藻类重新培养的非小细胞肺癌患者的脑转移。
DOI：
10.1016/j.lungcan.2015.01.020
发表时间：
2015-04
期刊：
Lung cancer (Amsterdam, Netherlands)
影响因子：
--
作者：
Rangachari D;Yamaguchi N;VanderLaan PA;Folch E;Mahadevan A;Floyd SR;Uhlmann EJ;Wong ET;Dahlberg SE;Huberman MS;Costa DB
通讯作者：
Costa DB
影响因子：
45.3
作者：
Gadgeel, Shirish M.;Shaw, Alice T.;Ou, Sai-Hong Ignatius
通讯作者：
Ou, Sai-Hong Ignatius
影响因子：
51.1
作者：
Gadgeel, Shirish M.;Gandhi, Leena;Ou, Sai-Hong Ignatius
通讯作者：
Ou, Sai-Hong Ignatius
影响因子：
2.5
作者：
Lei, Yuan-Yuan;Yang, Jin-Ji;Wu, Yi-Long
通讯作者：
Wu, Yi-Long
DOI：
10.1200/jco.2016.70.5749
发表时间：
2017-05-10
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Tamura T;Kiura K;Seto T;Nakagawa K;Maemondo M;Inoue A;Hida T;Yoshioka H;Harada M;Ohe Y;Nogami N;Murakami H;Kuriki H;Shimada T;Tanaka T;Takeuchi K;Nishio M
通讯作者：
Nishio M